Zevra Therapeutics (NASDAQ:ZVRA) vs. Reliv’ International (OTCMKTS:RELV) Head to Head Review

Reliv’ International (OTCMKTS:RELV) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Reliv’ International and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reliv’ International	-0.61%	-1.89%	-1.31%
Zevra Therapeutics	42.82%	54.54%	34.15%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Reliv’ International and Zevra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv’ International	0	0	0	0	0.00
Zevra Therapeutics	0	1	9	0	2.90

Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 136.33%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Reliv’ International.

Volatility and Risk

Reliv’ International has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Institutional & Insider Ownership

7.7% of Reliv’ International shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 30.0% of Reliv’ International shares are held by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Reliv’ International and Zevra Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv’ International	$35.06 million	0.09	-$440,000.00	($0.09)	-20.33
Zevra Therapeutics	$136.07 million	5.01	$83.23 million	$0.92	12.48

Zevra Therapeutics has higher revenue and earnings than Reliv’ International. Reliv’ International is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Zevra Therapeutics beats Reliv’ International on 13 of the 14 factors compared between the two stocks.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.